Journal SAM: Effectiveness and Safety of FDG-PET in the Evaluation of Dementia
Member Fee: Free
Non-Member Fee: $90.00
Release Date: 9/26/2013
Expiration Date: 9/26/2016
Continuing Education Credit Information
ABNM SAM Credit
The American Board of Nuclear Medicine has reviewed and approved this Journal SAM activity submitted by the SNMMI. This activity fulfills the requirements of the ABNM Maintenance of Certification program for self-assessment. 2.5 SAMs have been awarded for this activity.
AMA-PRA (Physician)
The Society for Nuclear Medicine and Medical Imaging, Inc. (SNMMI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
SNMMI designates this enduring material for a maximum of 2.5 AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Objectives
On successful completion of this activity, participants should be able to:
- Describe the added diagnostic value of FDG PET for assessment of dementia compared to clinical assessment and follow-up alone.
- Identify the pathophysiological substrate of cerebral glucose metabolism in neurodegeneration.
- Assess recent literature findings of levels of diagnostic evidence for FDG PET and Alzheimer's disease assessment.
- Recognize the inclusion of biomarker evidence, including FDG PET, in new diagnostic criteria for Alzheimer's disease.
- Describe effects of FDG PET on physician confidence when assessing a patient with suspected dementia.
Target Audience
The LLSAP is designed for all nuclear medicine specialists and other physicians, pharmacists and technologists who practice diagnostic and/or therapeutic nuclear medicine.
Faculty Disclosure(s)
Nicholas Bohnen, MD, PhD - no relevant relationships that could be perceived as a real or apparent conflict of interest.
David S.W.Djang, BA, MD - no relevant relationships that could be perceived as a real or apparent conflict of interest.
Karl Herholz, MD - no relevant relationships that could be perceived as a real or apparent conflict of interest.
Yoshimi Anzai, MD - no relevant relationships that could be perceived as a real or apparent conflict of interest.
Satoshi Minoshima, MD, PhD
Bayer Healthcare, Scientific Study/Trial; GE Healthcare, Other: Licensing; Hamamatsu Photonics, Consultant/Advisor; Hitachi Medical Systems, Scientific Study/Trial; Nihon Medi-Physics, Other: Donation; Philips Healthcare, Scientific Study/Trial. Other: Licensing
For questions please contact Lisa Lefebvre, Associate Director of Education, MOC at llefebvre@snmmi.org or 703-652-6783.
© 2014 SNMMI. All rights reserved. Policy on Privacy and Confidentiality: http://www.snmmi.org/index.cfm?PageID=926--
